Robert J Kinders

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 14:6877-85. 2008
  2. ncbi Development of a validated immunofluorescence assay for ?H2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, NationalCancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 16:5447-57. 2010
  3. ncbi Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells
    Lihua H Wang
    Laboratory of Human Toxicology and Pharmacology, Science Applications International Corporation, Frederick, MD, USA
    Clin Cancer Res 16:1073-84. 2010
  4. ncbi Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    Annamaria Rapisarda
    SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1867-77. 2009
  5. ncbi Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
    Thomas D Pfister
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1878-84. 2009

Collaborators

Detail Information

Publications5

  1. ncbi Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 14:6877-85. 2008
    ..S. Food and Drug Administration's Exploratory Investigational New Drug Application. Performance of the study design, needle biopsy procedure, and validated pharmacodynamic assay were evaluated in human tumor xenograft models...
  2. ncbi Development of a validated immunofluorescence assay for ?H2AX as a pharmacodynamic marker of topoisomerase I inhibitor activity
    Robert J Kinders
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick, Inc, NationalCancer Institute Frederick, Frederick, MD 21702, USA
    Clin Cancer Res 16:5447-57. 2010
    ..A quantitative pharmacodynamic immunofluorescence assay for ?H2AX was developed, validated, and tested in human tumor xenograft models with the use of clinically relevant procedures...
  3. ncbi Monitoring drug-induced gammaH2AX as a pharmacodynamic biomarker in individual circulating tumor cells
    Lihua H Wang
    Laboratory of Human Toxicology and Pharmacology, Science Applications International Corporation, Frederick, MD, USA
    Clin Cancer Res 16:1073-84. 2010
    ..Here, we describe an assay that directly examines changes in levels of the nuclear DNA damage marker gammaH2AX in individual CTCs of patients treated with chemotherapeutic agents...
  4. ncbi Increased antitumor activity of bevacizumab in combination with hypoxia inducible factor-1 inhibition
    Annamaria Rapisarda
    SAIC Frederick Inc, National Cancer Institue at Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1867-77. 2009
    ..These results strongly suggest that combination of anti-vascular endothelial growth factor antibodies with HIF-1 inhibitors is an attractive therapeutic strategy targeting in the hypoxic tumor microenvironment...
  5. ncbi Topoisomerase I levels in the NCI-60 cancer cell line panel determined by validated ELISA and microarray analysis and correlation with indenoisoquinoline sensitivity
    Thomas D Pfister
    Laboratory of Human Toxicology and Pharmacology, Applied Developmental Research Support Directorate, Science Applications International Corporation Frederick Inc, National Cancer Institute Frederick, Frederick, MD 21702, USA
    Mol Cancer Ther 8:1878-84. 2009
    ....